ONVO: Organovo Holdings Inc Company Value to Net Income

Organovo Holdings, Inc. (ONVO) is developing tissue bioprinting while remaining in the R&D stage with moderate dependence on macroeconomics and venture financing. The company maintains its leadership through unique organ models used for drug toxicity testing. Historical price action based on the PE multiple is -0.30, while the business minimizes costs by outsourcing cloud computing to external partners and retaining key patents.
Comprehensive metric breakdowns and analytics for Organovo Corp (ONVO)

The P/E ratio determines the cost of a single unit of profit, reflecting market expectations regarding business growth rates. This metric compares total market capitalization with net income to identify whether an asset is overvalued or undervalued. The stable supply of bio-inks and cultures provided by Organovo Holdings, Inc. (ONVO) minimizes operational risks, which should support earnings stability. By analyzing the current market P/E of Organovo Holdings, Inc. (ONVO), an investor can see the extent of the gap between price and actual earnings, allowing for an objective assessment of investment risks.